The ACTIV-3 clinical trial is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients.

Thursday, March 4, 2021 NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies of therapeutic agents. The Data and Safety Monitoring Board (DSMB) examined interim data on VIR-7831, and on a combination monoclonal antibody therapy containing BRII-196 and BRII-198. A DSMB analysis determined the therapeutics did not meet the inclusion criteria for further enrollment in the trial. There were no safety concerns with either therapeutic. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107